Table 1.

SRI-4 Response (%) at W48 in Primary Analysis and in Post-hoc Patient Subgroups

PBOFEN 150 mg QDFEN 200 mg BID
SRI-4 Response (%) at W4844
n=84		51
n=87		52
n=88
SRI-4 Response (%) in Baseline Subgroups
 At least 1 BILAG A48
n=42		54
n=39		59
n=46
 At least 1 BILAG A and SLEDAI increased DNA binding37
n=19		53
n=17		65
n=26
 SLEDAI arthritis with at least 4 swollen joints39
n=57		50
n=54		57
n=54
 SLEDAI arthritis with at least 4 tender joints39
n=71		53
n=70		59
n=69
 CLASI >=1021
n=14		36
n=11		31
n=16